Omeros (NASDAQ:OMER) Hits New 1-Year High – What’s Next?

Omeros Corporation (NASDAQ:OMER)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $19.65 and last traded at $19.2040, with a volume of 334942 shares changing hands. The stock had previously closed at $19.32.

Wall Street Analysts Forecast Growth

OMER has been the topic of several research reports. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Omeros Trading Down 5.5%

The firm has a market capitalization of $1.32 billion, a P/E ratio of 14.23 and a beta of 2.54. The firm has a 50-day moving average of $12.30 and a two-hundred day moving average of $11.92.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, sell-side analysts anticipate that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Insider Transactions at Omeros

In other news, Director Thomas J. Cable sold 15,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the transaction, the director directly owned 35,067 shares in the company, valued at $646,986.15. This trade represents a 29.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO David J. Borges sold 10,000 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,906 shares in the company, valued at approximately $111,918.70. This represents a 62.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 30,906 shares of company stock worth $568,305 over the last three months. Insiders own 10.50% of the company’s stock.

Institutional Trading of Omeros

A number of large investors have recently bought and sold shares of the business. UBS Group AG increased its stake in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after acquiring an additional 1,513,893 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Omeros by 85.2% during the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock worth $1,897,000 after acquiring an additional 82,646 shares in the last quarter. Corient Private Wealth LLC grew its holdings in Omeros by 13.0% in the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after purchasing an additional 79,263 shares during the period. Quantinno Capital Management LP increased its stake in Omeros by 145.4% in the first quarter. Quantinno Capital Management LP now owns 61,541 shares of the biopharmaceutical company’s stock valued at $650,000 after purchasing an additional 36,467 shares in the last quarter. Finally, Compass Financial Management LLC acquired a new position in shares of Omeros during the second quarter valued at about $312,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.